ANIK President/CEO bought 12,200 shares ($149.9K) at $12.29; holdings +50.9% to 36.2K shares amid unprofitable year
Griffin Stephen D., President and CEO of Anika Therapeutics, purchased 12,200 shares at $12.29 on 2026-04-30, increasing his holdings by 50.9% to 36,163 shares. The timing is notable given that the company posted net income of $-5,056,000.00 for its most recent full fiscal year and annual revenue declined 5.9% year-over-year. The purchase occurred while the stock trades -22.2% from its 52-week high and has declined 14.1% over the preceding 30 days, though it is up 34.9% over 90 days. An insider purchase of this magnitude from the company's top executive warrants attention to whether he views the depressed valuation as an opportunity, though the negative financial performance and revenue contraction present a countervailing risk signal that investors should weigh carefully.